Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than ...

Can the upcoming J.P. Morgan Healthcare Conference next week trigger a flurry of biotech M&A deal making activity. Read more ...

Here is a list of healthcare conferences and links to registration.  Special thanks to Peter Grant and Global Healthcare LLC ...

John Flavin, Portal Innovations CEO, joins 'Fast Money' to talk what we can expect to see from the J.P. Morgan Healthcare ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to ...

Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H'25 - - IND application for CRG-023 ...

Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

43rd Annual J.P. Morgan Healthcare Conference – Company Presentation Date: Wednesday, January 15, 2025 Time: 3:45 p.m. - 4:25 p.m. PT Location: The Westin St. Francis Hotel, San Francisco, CA ...

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...

Aktis Oncology, an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for large patient populations not addressed by existing platform technologies, ...